Cargando…
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
BACKGROUND: Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such engineered T cells cause significant safety challenges, such as cytokine releas...
Autores principales: | Zhang, Erhao, Gu, Jieyi, Xue, Jianpeng, Lin, Chenyu, Liu, Chen, Li, Mengwei, Hao, Jingchao, Setrerrahmane, Sarra, Chi, Xiaowei, Qi, Weiyan, Hu, Jialiang, Xu, Hanmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859748/ https://www.ncbi.nlm.nih.gov/pubmed/29558951 http://dx.doi.org/10.1186/s13045-018-0591-7 |
Ejemplares similares
-
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
por: Zhang, Erhao, et al.
Publicado: (2018) -
Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
por: Setrerrahmane, Sarra, et al.
Publicado: (2017) -
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
por: Li, Mengwei, et al.
Publicado: (2022) -
Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12
por: Chi, Xiaowei, et al.
Publicado: (2019) -
Tumor-related interleukins: old validated targets for new anti-cancer drug development
por: Setrerrahmane, Sarra, et al.
Publicado: (2017)